Parasite glycolytic pathway enzyme (null)

Parasite glycolytic pathway enzymes catalyze each step of glycolysis, which is the main metabolic pathway for energy production in many unicellular parasitic protozoa, including Plasmodium spp. (the causative agent of malaria), Trypanosoma, and Leishmania[1][2][7]. Unlike in mammalian cells, parasite glycolysis is often compartmentalized within organelles (glycosomes in trypanosomes) and displays structural differences from mammalian enzymes, allowing for potential selective drug targeting[1][2]. Key enzymes include hexokinase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase, and pyruvate kinase[2][4][7]. Inhibiting these enzymes starves the parasite of ATP and key biosynthetic precursors, ultimately leading to death. No licensed therapeutics currently target these enzymes directly, but several are under investigation as novel antiparasitic strategies[5][7]. Selectivity, resistance, and safety remain major challenges for drug development.

Other names

Glycolytic enzyme (parasite)Glycolytic pathway enzyme (parasite)Glycosomal enzyme (in kinetoplastids)Glycolysis enzyme (parasite)

Direct enzyme inhibition (e.g., active site inhibitors of hexokinase, phosphofructokinase, aldolase, etc.)[2][5][7]. Disrupting glycolytic enzyme localization (e.g., hindering glycosome import in trypanosomes)[1]. Reducing ATP generation, leading to parasite death[2][5][7].